Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR

World Journal of Gastroenterology

Volumn 17, Issue 12, 2011, Pages 1614-1621

  Pavlidou, Anastasia ^a   Dalamaga, Maria ^a   Kroupis, Christos ^a   Konstantoudakis, George ^a   Belimezi, Maria ^a   Athanasas, George ^a   Dimas, Kleanthi ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis gene; Colorectal adenocarcinomas; Lightcycler; mRNA isoforms; Real time quantitative polymerase chain reaction; Survivin

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; DYE; FLUORESCEIN; ISOPROTEIN; MESSENGER RNA; SURVIVIN; SURVIVIN 2B; SURVIVIN DELTAEX3; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79955938980     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i12.1614     Document Type: Article

References (45)

1. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-987
2. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002; 100: 30-36
3. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin CancerRes 2009; 15: 1126-1132
4. Fernández-Luna JL. Apoptosis regulators as targets for cancer therapy. Clin Transl Oncol 2007; 9: 555-562
5. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell 2010;17: 53-64
6. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivingene targeting. J Biol Chem 1998; 273: 11177-11182
7. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-2032
8. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70
9. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancertherapeutics. Clin Cancer Res 2008; 14: 5000-5005
10. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factorsand promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-623
11. Taubert H, Kappler M, Bache M, Bartel F, Köhler T, Lautenschläger C, Blümke K, Würl P, Schmidt H, Meye A, HauptmannS. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 2005; 24: 5258-5261
12. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006; 17: 597-604
13. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS, Guan XY. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006; 94: 108-114
14. Virrey JJ, Guan S, Li W, Schönthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008; 173: 575-585
15. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002; 43: 2249-2255
16. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102
17. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-907
18. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11
19. Mola G, Vela E, Fernández-Figueras MT, Isamat M, Muñoz-Mármol AM. Exonization of Alu-generated splice variants in the survivin gene of human and non-human primates. J Mol Biol 2007; 366: 1055-1063
20. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24: 1994-2007
21. Ling X, Cheng Q, Black JD, Li F. Forced expression of survivin- 2B abrogates mitotic cells and induces mitochondriadependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem 2007;282: 27204-27214
22. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 2006; 281: 16207-16219
23. Chen WC, Liu Q, Fu JX, Kang SY. Expression of surviving and its significance in colorectal cancer. World J Gastroenterol 2004; 10: 2886-2889
24. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expressionof survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 2005; 13: 891-897
25. Tan HY, Liu J, Wu SM, Luo HS. Expression of a novel apoptosis inhibitor-survivin in colorectal carcinoma. World J Gastroenterol 2005; 11: 4689-4692
26. Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004; 10: 3245-3250
27. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
28. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer2010; 46: 765-781
29. Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M, Lianidou ES. Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 2005; 38: 50-57
30. Huggett J, Dheda K, Bustin S, Zumla A. Real-time RT-PCR normalisation; strategies and considerations. Genes Immun 2005; 6: 279-284
31. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002; 29: 23-39
32. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, Bustin SA, Orlando C. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002; 309: 293-300
33. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of surviving isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006; 281: 1286-1295
34. Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 2005; 17: 42-50
35. Bustin SA, Benes V, Nolan T, Pfaffl MW. Quantitative realtime RT-PCR--a perspective. J Mol Endocrinol 2005; 34: 597-601
36. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-2104
37. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46: 645-650
38. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 inhematological malignancies. Leuk Res 2000; 24: 965-970
39. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91: 1204-1209
40. Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C, Rieber EP, Schmidt H, Bache M, Taubert H, Meye A. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001; 95: 360-363
41. Moriai R, Asanuma K, Kobayashi D, Yajima T, Yagihashi A, Yamada M, Watanabe N. Quantitative analysis of the antiapoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res 2001; 21: 595-600
42. Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004; 216: 147-155
43. Mandayam S, Huang R, Tarnawski AS, Chiou SK. Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells. Apoptosis 2007; 12: 1109-1116
44. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C. Identificationand validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-946
45. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003; 99: 738-745